Triple-negative breast cancers (TNBC) are the most aggressive subtype, accounting for about 15% of all breast cancers. TNBC has a high prevalence in central India, accounting for 43% of all breast cancers. Doxorubicin is the most effective chemothera
Section: Life Sciences & Biotechnology (Research Project)
Related:
Dual-targeted novel
Dual-targeted novel combination therapy for triple-negative breast cancer
Research Project › Pharmaceutical Sciences
Aptamer engineered
Aptamer engineered smart multifunctional dendrimer-BSA nano-architectures targeting stem cell marker CD133 for triple-negative breast cancer therapy
Research Project › Medical Sciences
EGFR targeted
EGFR targeted ‘Affimer’ recombinant proteins for targeted delivery of siRNA/drug loaded cubosomes to enhance treatment efficacy for drug resistant triple negative breast cancer.
Research Project › Life Sciences & Biotechnology
Development of
Development of novel biologics through engagement of innate or adaptive immunity for targeted immunotherapy of Triple Negative Breast Cancer
Research Project › Life Sciences & Biotechnology
Innovative Strategies
Innovative Strategies for targeted drug delivery in Triple Negative Breast Cancer: A Multi-stimuli Nanogel-Based Drug Delivery Approach
Research Project › Life Sciences & Biotechnology